George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
All this is before the airline industry fully opens up again also. I personally think it should stay shut until we see the result of the release of lockdown over the next 2 months, but that isn't going to happen. BJ has made many bad decisions, as well we know, and he can add that 1 to the list.
@MacTrader
Oh, without doubt the worldwide stage looks ugly, I see massive growth potential also in USA and Canada frankly and Diagnostics will become further valued as countries bolster their capabilities against future attacks.
Control of VOCs now is also cause for concern, so I do not see Novacyt being short of business anytime soon frankly!!!
The way I see it is that the market is factoring in worst case scenario here that an exceptional charge could be posted against Q4 earnings. Add to that lack of clarity on DHSC and forward trading and it all looks horrid. However, I do not share that view. Shortly the position will be confirmed one way or another, but I think it will be in our favour.
I was also encouraged by the Q1 worldwide result which was bloody superb. Stripping out the DHSC it was still coming in north of £ 35m, these are revenues some businesses on AIM could only ever dream of so I have total confidence that 2021 EBITDA and Cash at Bank will continue to remain strong.
This is now all about the forward statement, being part of the 4-year framework deal was a positive and imo some selective wins stateside, product innovations this quarter and some selective acquisitions will likely see the Share price rebound sharply. For this reason, I am holding on it, adding as I can afford and confident, they can do this.
In business nothing is easy, Novacyt have some challenges but they are not insurmountable. They also have imo one of the best R&D teams worldwide. Yes, they are sh@t at shareholder communication, but these are scientists we are talking about. Fundamentals will ultimately out here, and a decent PE ratio assigned and when they do the SP will be rated properly not this effective cash basis we currently trade at.
Here is to better days,
Pork’s
Cases in India OFFICIALLY at 90,000 a day but believed to be much higher, and rising exponentially. It is a reminder to us all not to get complacent. Cases in this country will go up now that we are out of lockdown, time will tell if it is to a manageable level. For my part not going to assume the vaccine is going to change things by itself. Diagnostics are here to stay, for this and future situations. This is our first line of defence now. This war is the biggest battlefront of my lifetime for sure.
Porky, definitely interesting to know from the end of year accounts when they are finally released what has been spent on R&D. I would like to think that they may have a few side projects going on quietly, maybe just wishful thinking. 1 thing is for sure, I applaud the speed at which we produce from concept to production, many companies small and large will be looking with envy.
As a longterm holder definitely get a lot of flack here. Not sure why, my investment here is just as important as someone who invested 2 months ago. Whilst there has been disappointment recently, if you told me where we would be in 13 months time I would definitely have been sceptical at the level of sales that we have achieved. All it goes to show is there is no limit to the capability of this company. For my part at least, looking forward to previous highs and beyond. Not sure how long it will take but my investment is going nowhere. I wish I could add, but maxed out.
Frustrating that the Share Price is still suffering despite cracking worldwide sales. The price drop feels well and truly overdone in comparison to fundamental strength.
All this at the backdrop of worsening worldwide conditions so you would be expecting the SP to rally, frankly. Time, however, can often be the biggest killer for Retail. We live in an instant world and Novacyt are building a business that takes time without updates Retail get bored.
Until the company update us, we remain in the dark and that of course creates the uncertainty that shorter’s and other pond life feed off.
Fortunately, I expect matters to change shortly: -
• Full Audited Results Due which we know will be superb.
• 311.6m Revenue / 210.8m EBITDA / 101m Cash
• Either Confirmation of Dispute resolved OR provision statement clarity one way or another
• 2nd Gen Antibody LFT release
• Antigen LFT release
• H1 Results
• Strategy on Direction of Group
It would be good to have an update regarding how the Genotype Testing Assay fits in. Visibility on How the two subsidiary businesses fare in relation to both the Lot 1 £ 3bn framework tender and the partner supply deals to the companies in the Lot 3 tender.
I am still curious as to what the point of all that data on Saliva samples with AZN was all about? I cannot see the point of proving a case if nothing is then done with the data.
Finally, can we win anything major stateside? They have all the accreditations in place now, so it is a matter of time. Is the business going to do anything regarding acquisitions? I mean we are fast approaching end of April and still nothing, you would expect a deal of some kind by now? OR is it us that is now the prey???
Anyhow, good luck holders, we will soon know one way or another. I am still adding.
Pork’s